Blue Owl’s Loparex Slips Toward Bankruptcy After Failed Deal
Blue Owl Capital marked down loans tied to Loparex from $122.43M to $8.34M after a failed merger, pushing Loparex into forbearance. Loparex's second lien debt fell over 94%. Loparex represented less than 1% of OBDC's portfolio, but investor nerves persist due to valuation uncertainties in private credit.
How this was made
The 30-second read
Why it matters
The fund’s NAV gap widens, likely prompting share price pressure and heightened scrutiny of similar credit holdings.
Market read
The unexpected loss on a material loan position creates immediate downside risk for OWL shares and may influence investor sentiment toward the broader private‑credit sector.
What to watch
Potential recovery value from Loparex restructuring could mitigate the loss over the longer term.
Background
Blue Owl Capital Corp (OWL) is a publicly traded private‑credit fund; Loparex is a specialty paper manufacturer whose loan exposure was heavily marked down after a failed recapitalization.
Ticker impact
Blue Owl Capital Corp disclosed a 93% markdown of its Loparex loans, cutting their value to $8.34 million, which sharply impacts the fund’s NAV and share price.
Potential short‑term decline in OWL share price as investors reassess NAV gap.
A large, unexpected loss on a material portfolio holding directly reduces fund assets and triggers market reaction.
Market effects
Highlights credit‑risk concerns in private‑credit funds, may affect peer fund valuations.
U.S. private‑credit market perception could tighten funding conditions.
Limited to fund investors; no broad macro impact.
Counterpoint
If the write‑down is isolated, OWL may be undervalued and present a buying opportunity at a discount to NAV.
Key entities
- FundBlue Owl Capital Corp
Publicly listed private‑credit manager (ticker OWL).
- Private CompanyLoparex
Specialty paper and liner manufacturer whose loans were marked down.
